To date, the prognostic index derived by Beyer et al (1996) which identifies disease site at presentation, level of hCG prior to HDCT and sensitivity to last cisplatin-based conventional chemotherapy regimen has proved to be the most useful way of predicting progression-free and overall survival following HDCT.
A raised lactate dehydrogenase (LDH) prior to induction chemotherapy predicted a poor outcome (only 1/10 progression free at 2 years versus 11/15 if normal, P = 0.049). The predictive value of this exceeds that of conventional tumour markers. Two therapeutic manoeuvres -namely the introduction of paclitaxel into induction therapy (TIP) and the dosing of carboplatin using AUC rather than mg m -2 in combination with etoposide and an oxazophosphorine -were also examined. Paclitaxel did not appear to have improved outcome. Initially as part of the high-dose regimen patients received carboplatin with dosage calculated on the basis of mg m -2 . Subsequently dosing was changed to one using an AUC formula (Calvert et al, 1989) . Recalculating the dosage to express it as an AUC was possible since patients had an EDTA clearance prior to HDCT. This enabled examination of the impact of the carboplatin AUC dose. There was no suggestion that higher doses of carboplatin were more effective.
We believe the observation of a raised LDH at induction carrying a poor prognosis needs to be validated, as the test is simple and in first line therapy increasingly recognized to be as good if not better than hCG as prognostic factor outcome (Mead Letters to the Editor Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy
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British Journal of Cancer (2000) 82 (12), 2022 -2023 © 2000 Cancer Research Campaign doi: 10.1054 / bjoc.1999 .1140 , available online at http://www.idealibrary.com on Fosså and Kravdal (2000) found that men with testicular cancer were subfertile both before and after diagnosis. Møller (1998) reported that men with testicular cancer sired significant excesses of daughters both before and after diagnosis. Fosså and Kravdal (2000) wrote that 'the low fertility after diagnosis may be partly due to the continuing inherent influence of a sub-or in-fecundity that also had a bearing on the development of the disease'. Any cause of both the subfertility and the low offspring sex ratio (proportion male) would therefore seem a promising candidate also as a cause of the disease, so I should like to suggest one.
Sir
I have adduced very substantial quantities of data to support the hypothesis that the sexes of mammalian (and among them, human) offspring are partially dependent on the hormone levels of both parents around the time of conception (James, 1996) . Ex hypothesi, low androgen levels in either parent are associated with the subsequent production of daughters. Moreover, levels of androgens (particularly dihydrotestosterone) in men are positively associated with coital rates (Dabbs and Morris, 1990; Mantzoros et al, 1995) : and coital rates are powerfully and positively associated with fecundability, the probability of conceiving in a month at risk (Potter and Millman, 1986) . Accordingly, I suggest that one cause of testicular cancer is suboptimal androgen levels. These, in turn, may be influenced by the intrauterine environment in which the patient gestated.
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